Ifosfamide in urologic cancer

F. Boccardo, P. Guglielmini

Research output: Contribution to journalArticle

Abstract

The therapeutic activity of ifosfamide in urologic tumors has been reviewed. Ifosfamide has definite activity in nephroblastoma, where it represents the treatment of choice for children who are not cured by front-line chemotherapy, and for the adults who are diagnosed with this uncommon disease. Definite therapeutic activity has also been shown in patients with urothelial tract malignancies and it represents a major option for patients failing first-line cisplatin-based chemotherapy. However, promising results have been achieved in chemo-naïve patients in combination with taxanes or gemcitabine, though at the price of relevant toxicity. A modest activity has been shown by ifosfamide in renal cancer (including the sarcomatoid variant) and in hormone-refractory prostate cancer, which unfortunately respond poorly to cytotoxic chemotherapy. No results of ifosfamide in penile carcinoma are available so far.

Original languageEnglish
Pages (from-to)67-72
Number of pages6
JournalOncology
Volume65
Issue numberSUPPL. 2
DOIs
Publication statusPublished - 2003

Fingerprint

Urologic Neoplasms
Ifosfamide
gemcitabine
Drug Therapy
Taxoids
Wilms Tumor
Kidney Neoplasms
Cisplatin
Neoplasms
Prostatic Neoplasms
Therapeutics
Hormones
Carcinoma

Keywords

  • Ifosfamide
  • Urologic cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ifosfamide in urologic cancer. / Boccardo, F.; Guglielmini, P.

In: Oncology, Vol. 65, No. SUPPL. 2, 2003, p. 67-72.

Research output: Contribution to journalArticle

Boccardo, F & Guglielmini, P 2003, 'Ifosfamide in urologic cancer', Oncology, vol. 65, no. SUPPL. 2, pp. 67-72. https://doi.org/10.1159/000073363
Boccardo, F. ; Guglielmini, P. / Ifosfamide in urologic cancer. In: Oncology. 2003 ; Vol. 65, No. SUPPL. 2. pp. 67-72.
@article{90d79a9d31604622b8b818af53ab2522,
title = "Ifosfamide in urologic cancer",
abstract = "The therapeutic activity of ifosfamide in urologic tumors has been reviewed. Ifosfamide has definite activity in nephroblastoma, where it represents the treatment of choice for children who are not cured by front-line chemotherapy, and for the adults who are diagnosed with this uncommon disease. Definite therapeutic activity has also been shown in patients with urothelial tract malignancies and it represents a major option for patients failing first-line cisplatin-based chemotherapy. However, promising results have been achieved in chemo-na{\"i}ve patients in combination with taxanes or gemcitabine, though at the price of relevant toxicity. A modest activity has been shown by ifosfamide in renal cancer (including the sarcomatoid variant) and in hormone-refractory prostate cancer, which unfortunately respond poorly to cytotoxic chemotherapy. No results of ifosfamide in penile carcinoma are available so far.",
keywords = "Ifosfamide, Urologic cancer",
author = "F. Boccardo and P. Guglielmini",
year = "2003",
doi = "10.1159/000073363",
language = "English",
volume = "65",
pages = "67--72",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Ifosfamide in urologic cancer

AU - Boccardo, F.

AU - Guglielmini, P.

PY - 2003

Y1 - 2003

N2 - The therapeutic activity of ifosfamide in urologic tumors has been reviewed. Ifosfamide has definite activity in nephroblastoma, where it represents the treatment of choice for children who are not cured by front-line chemotherapy, and for the adults who are diagnosed with this uncommon disease. Definite therapeutic activity has also been shown in patients with urothelial tract malignancies and it represents a major option for patients failing first-line cisplatin-based chemotherapy. However, promising results have been achieved in chemo-naïve patients in combination with taxanes or gemcitabine, though at the price of relevant toxicity. A modest activity has been shown by ifosfamide in renal cancer (including the sarcomatoid variant) and in hormone-refractory prostate cancer, which unfortunately respond poorly to cytotoxic chemotherapy. No results of ifosfamide in penile carcinoma are available so far.

AB - The therapeutic activity of ifosfamide in urologic tumors has been reviewed. Ifosfamide has definite activity in nephroblastoma, where it represents the treatment of choice for children who are not cured by front-line chemotherapy, and for the adults who are diagnosed with this uncommon disease. Definite therapeutic activity has also been shown in patients with urothelial tract malignancies and it represents a major option for patients failing first-line cisplatin-based chemotherapy. However, promising results have been achieved in chemo-naïve patients in combination with taxanes or gemcitabine, though at the price of relevant toxicity. A modest activity has been shown by ifosfamide in renal cancer (including the sarcomatoid variant) and in hormone-refractory prostate cancer, which unfortunately respond poorly to cytotoxic chemotherapy. No results of ifosfamide in penile carcinoma are available so far.

KW - Ifosfamide

KW - Urologic cancer

UR - http://www.scopus.com/inward/record.url?scp=0242351644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242351644&partnerID=8YFLogxK

U2 - 10.1159/000073363

DO - 10.1159/000073363

M3 - Article

C2 - 14586152

AN - SCOPUS:0242351644

VL - 65

SP - 67

EP - 72

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - SUPPL. 2

ER -